Summary.-During the terminal stages of tumour growth (6-8 weeks) in Wistar rats bearing a syngeneic squamous cell carcinoma (Spl), their sera can block in vitro anti-tumour cytotoxicity by immune splenic T lymphocytes. At an earlier stage of tumour growth (4-6 weeks) the sera do not block this cytotoxicity, but can induce anti-tumour cytotoxicity by non-immune spleen cells in the absence of complement. Sera taken at these 2 stages of tumour growth have been fractionated by ion-exchange chromatography, using DEAE-cellulose. The fractions have been examined by immunoelectrophoresis and tested for anti-tumour reactivity. Blocking activity was found in the Week-8 serum fraction eluted with 0005M phosphate buffer, pH 7-4, whilst the " cytotoxic " activity of Week-4 serum was eluted with 0-02M phosphate buffer, pH 6-2. It is suggested that different IgG sub-classes are responsible for the 2 activities.
IN RATS bearing a syngeneic squamous cell carcinoma (Spl), in vitro anti-tumour cytotoxicity by splenic T lymphocytes can be detected 4 weeks after tumour induction, and persists until death of the host after 8 weeks (Flannery et al., 1973a; Matthews et al., 1976) . After 6 weeks of tumour growth, factors appear in the serum, capable of blocking this cytotoxicity. The serum effect is expressed at the tumour-cell and not at the lymphocyte level, suggesting a role for antitumour antibodies, or perhaps complexes of these antibodies and tumour-derived antigen in antibody excess.
At an earlier stage of tumour growth (4-6 weeks), at the height of the complement-dependent antibody response to the tumour, sera at high dilutions can induce in vitro anti-tumour cytotoxicity by non-immune spleen cells in the absence of complement (Flannery et al., 1973b; Matthews et al., 1976 (Flannery et al., 1973b) . Briefly, 10 ,ul of heat-inactivated serum or serum fractions was incubated for 1 h at 37°C with 50-100 plated Spl tumour cells in Falcon microtest plates (3034). The plates were washed once, and cytotoxic spleen cells were added in a volume of 10 ,ul to give an effector:target cell ratio of 100:1. After a 4-h incubation at 37°C, plates were washed gently to remove spleen cells nonadherent to Spl cells, and then the incubation w,as continued for a further 2 days. The plates were washed and fixed, and the remaining tumour cells in each well were counted by phase-contrast microscopy. Percent blocking was calculated as 100 (Cn-Ct)/ Cn where Cn and Ct are respectively the cytotoxicities of the spleen cells in the presence of normal and test sera. For specificity tests of serum blockade, spleen cells from a DA rat that had borne the MRMC2 tumour for 10 days were used as cytotoxic cells, and normal DA spleen cells were used as controls.
Antibody-induced lymphoid cell cytotoxicity was determined as described previously (Matthews et al., 1976) Ion-exchange chromatography.-Sera were pooled from 4 animals after 4 or 8 weeks of tumour growNth. One ml of heat-inactivated serum was exhaustively dialysed against O-O1M phosphate buffer, pH 7*4, and applied to a 5-ml bed volume column of DEAEcellulose (Whatman 52) equilibrated with the same buffer. Stepwise elution at room temperature was performed with the following buffers: 0-O1M, pH 7-4 (Fraction I); 0-02M, pH 6-2 (Fraction II); 0(05M, pH 4*5 (Fraction III) and 0-2M, pH 4-5 (Fraction IV). In one experiment, the serum and column were equilibrated with 0-005M phosphate buffer, pH 7 4, and elution was performed initially with the same buffer (Fraction I') and then with the following phosphate buffers: 0O01M, pH 7-4 (Fraction II'); 0-02M, pH 6-2 (Fraction III') and 0-2M, pH 4-5 (Fraction IV'). Fractions eluted with each buffer were dialysed against isotonic saline and concentrated to 1 ml by negative pressure dialysis and then niembrane-sterilized.
Immunoelectrophoresis.-The method of Scheidegger (1955) was employed, using 1-3%o Oxoid Jonagar No. 2 in a veronal buffer of ionic strength 0f025M and pH 8 2. The antiserum was raised in a rabbit against a y-globulin fraction precipitated from rat serum with 330/,, saturated ammonium sulphate solution.
Absorption uith anti-IgG.-Tumour-bearer sera and their fractions were tested for activity after absorption with a rabbit anti-rat IgG serum that had been polymerized with glutaraldehyde. The rabbit anti-rat IgG was prepared by immunization with DEAE-cellulose-purified rat IgG and on immunoelectrophoresis gave a single precipitin line against whole rat serum. The anti-IgG serum was rendered insoluble by the method of Avrameus and Ternynck (1969) . Briefly, 1 ml of IM phosphate buffer, pH 7 0, was added to 10 ml of serum, and 3 ml of 2.5% glutaraldehyde was added slowly, witl-h stirring at room temperature. After 3 h, the gel that formed was homogenized in 0-2M phosphate buffer, pH 7 0, and centrifuged at 3000g for 15 min.
The gel was washed a further 4 times, the final time in phosphate-buffered saline. For absorption, 0 3 ml of packed gel was incubated with 0-2 ml of whole serum or fractions, diluted 1 in 5, for 1 h at room temperature.
RESULTS
Week-4 and Week-8 sera gave very similar elution profiles when fractionated by ion-exchange chromatography under identical conditions (Fig. 1, top and centre). The eluates were pooled into 4 fractions, I-IV, and tested for ability to block cytotoxicity by immune spleen cells from tumour-bearing rats. Table I shows that most of the blocking activity of Week-8 serum is contained in Fraction I; there was no such activity in Week-4 serum or any of its fractions. Using different elution conditions (Fig. 1,  bottom) , the blocking activity of Week-8 serum was again found in the first fraction eluted (Fraction I'); in this case with 0-005M phosphate buffer, pH 7*4. Fraction I' reacted with anti-immunoglobulin 
FIG. 1. Fractionation of Week-4 (top) and
Week-8 (centre and bottom) sera by stepwvise ion-exchange chromatography using DEAE-cellulose and phosphate buffers. (Table II) . The immunoelectrophoretic distribution of Fractions I-IV of Week-4 serum is shown in Fig. 2c-f ; of Fractions I-IV and Fractions I'-IV' of Week-8 serum in Fig. 2g-j (Table I) , and the ability to induce cytotoxicity by normal spleen cells found in Week-4 serum and Fraction II of it (Table II) were abolished by absorption with insoluble anti-IgG. Neither Week-4 serum nor any of its fractions could evoke cytot6xicity mediated by normal spleen cells against the tumours Sp24, Mc7 or MRMC2 (Table  III) . Similarly, neither Week-8 serum nor any of its fractions could block cytotoxicity against MRMC2 cells effected by DA spleen cells immune to MRMC2.
Serum fraction
% Cytotoxicity 18-4* -7-0 21-7* -5-2 -7 9 -2-5 6-3 -0-6 9-2 -6-9 -1-5 of both the blockade and the antibodydependent cytotoxicity, established by the negative results with the control tumours (Table III) , is further evidence of the antibody nature of the active serum components.
The elution buffers to obtain the serum fractions were similar to those used by others (Bloch, Morse and Austen, 1968; Jones, Edwards and Ogilvie, 1970) who found that these buffers separated rat IgG sub-classes. Although specific anti-sub-class sera were not available to identify our serum fractions, the immunoelectrophoretic analysis of the fractions shows that they differ in charge as well as function, and the assumption that they contain different IgG subclasses seems justified.
The factors that block lymphocyte cytotoxicity in Week-8 sera do not behave as anything other than free antibody molecules. There is no evidence that they are complexes, as have been demonstrated for other systems (Sjogren et al., 1971; Baldwin, Price and Robins, 1972) , although they have not been subjected to rigorous dissociating conditions.
The antibody which induces cytotoxicity by non-immune spleen cells (i.e. K cells and macrophages) does not block cytotoxicity by immune splenic T lymphocytes, and thus may bind to different Spl antigens from those recognized by the T cells. However, blocking antibody and cytotoxic T cells must compete for the same, or adjacent, antigenic determinants. These determinants may be so distributed on the tumour cell surface, that the Fc region of the blocking antibody is not sufficiently altered to bind to, and hence activate, K lymphocytes or macrophages.
Alternatively, pos4ible differences in antibody sub-class suggest that blocking antibodies bound to tumour cells do not have the appropriate configuration in their Fc regions to activate antibodydependent cytotoxic cells.
